How long does it take for Ibrutinib to take effect?

Ibrutinib belongs to the kinase inhibitor class of drugs. It works by blocking the activity of abnormal proteins. This abnormal protein is a signal for cancer cell reproduction, which helps prevent the spread of cancer cells. Ibrutinib is indicated for the treatment of patients with mantle cell lymphoma who have been treated with at least one other chemotherapy agent, the treatment of patients with chronic lymphocytic leukemia (CLL)( and small lymphocytic lymphoma, the treatment of Waldenström giant ball Proteinemia, treatment of patients with marginal zone lymphoma, and treatment of patients with chronic graft-versus-host disease(cGVHD) Complications of hematopoietic stem cell transplantation that can begin some time after transplantation and persist long after treatment with one or more drugs fails.

Typically, very good partial clinical responses to ibrutinib may occur within three to six months. It is not uncommon for white blood cell counts to increase during initial treatment with ibrutinib. In clinical trials, high lymphocyte counts have been reported in up to 57% to 69% of people. After ibrutinib was found in 77 (57%) of 1patients, these symptoms resolved in 95% of patients after 12weeks. This lasted for 12 to 14 weeks, with 94% to 95% of patients experiencing remission. Response to treatment and survival without cancer progression were similar in people with high lymphocyte counts during initial treatment and in people without high lymphocyte counts. Regardless of clinical response, most people are placed on ibrutinib indefinitely. This is a common treatment strategy for people with certain types of leukemia and solid tumors because often when the therapeutic agent is stopped, symptoms return within a relatively short period of time and the lymph nodes enlarge, especially if the patient has not been taking ibrutinib for a long time or if they have tried many other previous treatments.

The average duration of ibrutinib therapy in clinical trials was approximately 41 months (range 2-51 months)). Among patients who discontinued ibrutinib, the median survival after discontinuation was 8 months. There are generic drugs in Bangladesh, Laos and India, with different manufacturers, different specifications, and different prices. The price per box is about 1000 to2000 and more. Patients can choose the drug version according to their own financial situation. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.